CRVO
CervoMed Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.31
+3.12%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -27.6%
- EBIT
- -26.9%
- EPS
- -24.4%
- Free cash flow
- -20.0%
- Operating cash flow
- -20.0%
Forward estimates
Based on analyst estimates
- Revenue
- +197.1%
- EBITDA
- +50.4%
- EPS
- +54.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- -65.5%
- EBIT
- -55.2%
- Net income
- -65.5%
- EPS
- -47.5%
- Free cash flow
- -41.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026